As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
9 Analysts have issued a Agenus Inc. forecast:
9 Analysts have issued a Agenus Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 107 107 |
33%
33%
|
|
| Gross Profit | 106 106 |
34%
34%
|
|
| EBITDA | -50 -50 |
41%
41%
|
|
| EBIT (Operating Income) EBIT | -63 -63 |
38%
38%
|
|
| Net Profit | -35 -35 |
84%
84%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
| Head office | United States |
| CEO | Garo Armen |
| Employees | 316 |
| Founded | 1994 |
| Website | agenusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


